At ELECTRONICA, ITEN Present an Autonomous Asset Monitoring Solution Based on a 100µA.h Micro-Battery!
ITEN, the deep tech company, which just closed a financing round of 80M€ to become a key player in the manufacture of solid-state lithium-ion micro-batteries, shall take the opportunity of next ELECTRONICA exhibition to present a breakthrough in the way of powering autonomous embedded systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005719/en/
Ecofriendly and powerful soli-state micro-battery able to recharge in a few minutes. (Photo: ITEN)
When observing the battery-powered electronic solutions, ITEN came indeed to the following conclusions:
- A lot of electronic designs relies on very polluting coin cells, difficult to assemble on Printed Circuit Boards, costly to recycle and requiring periodic maintenance to replace the battery once empty.
- Depending on the countries, only 30 to 50% of such coin cells are effectively recycled.
- Autonomous embedded systems require less and less energy to operate; however, from time to time, the power supply must deliver high current pulses for instance to drive RF transceivers or actuators; therefore, most electronic designers must use oversized coin cells because such batteries are known to deliver only small currents.
From a battery standpoint, this means that a lower battery capacity could be used if the battery would be able to deliver the required power and could be recharged regularly.
This is precisely what ITEN shall demonstrate during ELECTRONICA: ITEN shall indeed present an autonomous asset monitoring solution, including sensors and a Bluetooth Low Energy (BLE) System-on-a-chip, and powered by the combination of an indoor photovoltaic cell from DRACULA Technologies (LAYERR Technology) and ITEN’s powerful rechargeable SMD micro-battery of only 100µA.h. The solution operating 24/7 can send data every 10 seconds during the day and every 4 to 5 minutes during the night (this frequency could be increased if using a 250µA.h micro-battery instead). By comparison, a coin cell of at least 100mA.h would be required to get the same operating conditions but with a limited lifetime.
By extension, similar designs could be used in applications like BLE asset tracking, BLE tags, beacons, and sensor data loggers.
On stand B4-120, ITEN shall also demo micro-batteries used as a back-up power supply to keep some clocks or microcontrollers active or to send maintenance alerts in case of failure of the main power source.
By doing so, ITEN clearly reassert their strategy to progressively replace most of the coin cells used worldwide by ecofriendly rechargeable SMD micro-batteries containing neither heavy metals, nor toxic materials, nor organic solvents and showing a carbon footprint 200 to 1000 times less compared to coin cells.
After 8 years of R&D, ITEN have been granted more than 200 patents worldwide. ITEN are an integrated device manufacturer, controlling the complete production chain from nanomaterial synthesis up to the battery packaging and test. Even with low capacities, ITEN micro-batteries can deliver power and high current pulses. They are a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.
About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to power autonomous sensor nodes or in applications like tracking and monitoring, smartphone peripherals, smart cards, medical devices, home and building automation, smart cities, wearables, and e-textiles.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005719/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
